![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, October 11, 2021 6:06:25 PM
NV-CoV-2-R is safer than a vaccine; here’s why. The body’s natural defense is the strongest, provided that it can mount a successful immune response. When the body defeats the virus, it is naturally immune, stronger than (mRNA) vaccines. The body’s defense is the best of all.
mRNA vaccines express the spike in your body to attract immune responses. But the breakthrough infections tell us that the body is getting rid of the immune cells, allowing reinfection and encouraging mutations - - COVID VARIANTS. The reason why COVID infects is because it is a retro virus. It enters the immune cell and reprogram a it to make more viruses. The virus attacks and hijacks the body’s immune system.
NV-CoV-2-R is the best approach, because it mounts a synergistic attack that hijacks the virus spike protein, neutralizes and destroys the virus, and builds immunity all at once.
NV-CoV-2-R does not introduce mRNA and does not create variant mutations.
The virus is mutating the spike against the mRNA to reproduce and complete its life cycle. NV-CoV-2-R eliminates the virus’ ability to progress as soon as it attaches, without any mutations or variants. The body’s immune system becomes competent and the virus is compromised and destroyed.
NV-CoV-2-R actually enhances and assists the body’s immune system to be be effective and efficient in multiple ways. mRNA is extremely dangerous and mutagenic. NV-CoV-2-R is effective and stable.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM